These findings indicate that targeting the interaction between the proangiogenic factors secreted by cancer cells and the tumor microenvironment, specifically the IL-6 released by MSCs, may result in novel therapeutic and preventive approaches (225). This evidence concerns the gene IL6 and cancer.